drugset / Trial / NCT03897088
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.
Timeline
- Start
- 2019-03-29
- Primary completion
- 2022-02-17
- Completion
- 2022-02-17
Publications
- Sofen HL, Gogineni R, Nishandar T, Bagel J. Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks. Dermatol Ther (Heidelb). 2026 Jun;16(6):3151-3165. doi: 10.1007/s13555-026-01774-2. Epub 2026 May 9.
- Sofen HL, Gebauer K, Spelman L, Yamauchi PS, Yao SL, Nishandar T, Kopeloff I, Crane M, Gogineni R, Kothekar M, Bagel J. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2025 Apr;92(4):816-824. doi: 10.1016/j.jaad.2024.12.018. Epub 2024 Dec 23.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tildrakizumab | Monoclonal antibody | 100 mg | — |